September 2023 – Monthly portrait of a young researcher

Oliver Krigslund, Postdoctoral Researcher

Oliver Krigslund, associated with the Behrendt and Engelholm labs at the Finsen Laboratory, Rigshospitalet, has delved into targeted cancer therapy. With a PhD in Biochemistry from the University of Copenhagen, Oliver has several years of experience in antibody-drug conjugates (ADCs) development, specifically those aiming at tumor-associated macrophages (TAMs).

His expertise encompasses both in vivo and in vitro testing of ADCs, and through his extensive research, he has achieved proof-of-concept for novel ADCs in both these settings. This was evident during his PhD research where he used techniques like High-Performance Liquid Chromatography (HPLC) and MALDI-TOF mass spectrometry for ADC characterization and subsequently developed a transgenic mouse model that targets TAMs with diphtheria toxin (DT).

As he continues his research journey, Oliver’s focus remains on refining ADCs for both cancer cells and the tumor stroma to further their effectiveness in cancer treatment.

Research focus:

Targeted cancer therapy, Antibody-drug conjugates (ADCs) development and testing, tumor-associated macrophages (TAMs), In vivo and In vitro proof-of-concept for novel ADCs, Techniques for ADC characterization, Mouse models in cancer research

WP relation:

WP13 and WP4, WP3